The Information Exists.
The Access Doesn't.

Over 2 million Americans are diagnosed with cancer each year. An estimated 10,000–20,000 of them could benefit from personalized neoantigen vaccines — treatments custom-built to target their tumor's unique mutations.

Roughly 30 patients per year actually receive them.

Why the Gap Exists

visibility_off

Patients Don't Know

Most patients and even many oncologists are unaware that personalized cancer vaccines are available outside of clinical trials through FDA expanded access programs. The research exists in medical journals, not patient-facing resources.

account_tree

The Process Is Complex

Getting a personalized vaccine requires coordinating across genomic sequencing labs, bioinformatics platforms, GMP manufacturing facilities, the FDA, and an administering oncologist. No single entity manages the entire process.

payments

Cost Is a Barrier

At $100,000–$119,000 and not covered by insurance, the financial burden is significant. Few resources exist to help patients understand what they're paying for or how to access financial assistance.

What ImmunaPath Does

ImmunaPath is a research and navigation resource for patients, families, and physicians exploring personalized cancer vaccines. We provide:

school

Plain-Language Research Updates

Weekly newsletter translating clinical trial results, FDA decisions, and scientific developments into language patients and families can understand.

checklist

Interactive Decision Tools

Free eligibility assessments and cost calculators to help you understand your options before talking to your doctor.

menu_book

Comprehensive Guides

In-depth explanations of FDA expanded access, the treatment process, costs, legal frameworks, and what questions to ask your oncologist.

What We Are Not

Transparency matters, especially in healthcare. Here's what ImmunaPath is not:

  • × Not a medical provider. We do not diagnose, prescribe, or treat. All medical decisions are between you and your physician.
  • × Not a substitute for your oncologist. Our tools provide general guidance. Your doctor has your complete medical picture.
  • × Not making promises. Personalized cancer vaccines are an emerging field. Results vary. Not every patient is a candidate, and not every treatment succeeds.
  • × Not selling treatment. We don't manufacture vaccines, sell medical products, or profit from your treatment decisions.

The Landscape in Numbers

$208M

Market size (2024)

~$2.7B

Projected by 2030

99%

FDA expanded access approval rate

49%

Recurrence reduction (Phase 2b, melanoma)

Start Here

Whether you're a patient, family member, or physician — we'll help you understand what's possible.

Check Eligibility Estimate Costs Subscribe